Journal Article
Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022–2023
Jacqueline Findlay; Otavio Hallal Ferreira Raro; Laurent Poirel; Patrice Nordmann; R. Lienhard; L. Vonallmen; C. Schilt; A. Scherler; K. Lucke; M. Jutzi; M. Reichmuth; U. Schibli; C. Fricker; S. Pranghofer; G. Greub; D. Blanc; A. Vitale; B. Lemaire; M. Fatoux; M. Tritten; L. Rumebe; N. Liassine; G. Jost; N. Wohlwend; D. Schultze; K. Burren; A. Westers; M. Imperiali; L. Pozzi; D. Balzari; G. Vaninetti; C. Cirillo; V. Gaia; E. Pianezzi; G. Martinetti Lucchini; F. Baggi Menozzi; A. Jayol; C. Guyon; D. Hyden; M. Maitrejean; V. Deggi-Messmer; D. Bandeira; C. Fournier; S. Pfister; C. Nusbaumer; L. Bertaiola Monnerat; J. Schrenzel; G. Renzi; A. Cherkaoui; D. Andrey; S. Emonet; M. Eyer; R. Maret; A. Belo; D. Mabillard; M. Moraz; K. Herzog; V. Gisler; E. Hitz; M. Oberle; C. Castelberg; H. Fankhauser; S. Graf; N. Dubey; C. Guler; M. Schoenenberger; U. Karrer; F. Piran; C. Andreutti; M. Dessauges; T. Schmid; B. Suterbuser; I. Mitrovic; E. Gruner; V. Bruderer; P. Staehli; B. Schnell; C. O. Marti; I. Steffen; A. Imhof; B. Preiswerk; V. Dilorenzo; C. Payen; D. Boschung; L. Comte; M. Schacher; M. Brandenberger; C. Zowa; C. Zehnder; B. Mathis; L. Basilico; G. Togni; P. Minkova; Y. Born; M. Kuegler; V. Povolo; S. Droz; M. Elzi; C. Casanova; D. Goldenberger; P. Keller; C. Lang; A. Blaich; S. Schmid; B. Ivan; A. Egli; S. Mancini; O. Dubois; K. Narr; S. Schoch; S. Ellenberger; S. Seiffert
European Journal of Clinical Microbiology & Infectious Diseases · Vol. 43, Issue 3 · pp. 551-557 · 2024
Abstract
Objectives The occurrence of metallo-beta-lactamase-producing Pseudomonas aeruginosa (MBL-PA) isolates is increasing globally, including in Switzerland. The aim of this study was to characterise, phenotypically and genotypically, the MBL-PA isolates submitted to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) reference laboratory over a 12-month period from July 2022 to July 2023. Methods Thirty-nine non-duplicate MBL-PA Isolates were submitted to NARA over the study period from across Switzerland. Susceptibility was determined by broth microdilution according to EUCAST methodology. Whole-genome sequencing was performed on 34 isolates. Sequence types (STs) and resistance genes were ascertained using the Centre for Genomic Epidemiology platform. MBL genes, bla NDM-1 , bla IMP-1 , and bla VIM-2 , were cloned into vector pUCP24 and transformed into P. aeruginosa PA14. Results The most prevalent MBL types identified in this study were VIM (21/39; 53.8%) followed by NDM (11/39; 28.2%), IMP (6/39; 15.4%), and a single isolate produced both VIM and NDM enzymes. WGS identified 13 different STs types among the 39 isolates. They all exhibited resistance to cephalosporins, carbapenems, and the beta-lactam-beta-lactamase inhibitor combinations, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam, and 8 isolates were cefiderocol (FDC) resistant. Recombinant P. aeruginosa strains producing bla NDM-1 , bla IMP-1 , and bla VIM-2 exhibited FDC MICs of 16, 8, and 1 mg/L, respectively. Conclusions This study showed that the MBL-PA in Switzerland could be attributed to the wide dissemination of high-risk clones that accounted for most isolates in this study. Although FDC resistance was only found in 8 isolates, MBL carriage was shown to be a major contributor to this phenotype.